Summit Therapeutics Share Discussion Threads

[hernando2] 27/2/2019 15:41

basically the company is owned by Mr Duggan on behalf of his fund, based in America he is likely promoting the backside out of it...hopefully onwards and upwards.

[waterloo01] 27/2/2019 15:08

Through $2.00 on Nasdaq. Equates to 30p and a break out of the range and on another day of good volume. Re-rate?

[waterloo01] 27/2/2019 14:33

With thanks to pharmagiles on III,

If you can't download the full paper - the expert opinion concludes

Ridinilazole is a novel antibiotic with ideal properties for the
treatment of CDI. Namely, it has a very narrow spectrum of
activity that causes minimal killing of the host microbiota while
displaying potent activity against clinical strains of C. difficile. It
is non-absorbable providing large concentrations to the colon
when delivered orally. Given that it is not absorbed systemically,
it is expected that ridinilazole should have a favorable safety
profile including a lack of drug interactions and systemic toxicities;
results that have been confirmed to date. Given the
promising results from the phase II clinical trial, ridinilazole
may be able to lower the risk for CDI recurrence thus improving
sustained clinical response rates; a current unmet medical need.

As the importance of CDI recurrence continues to be appreciated,
ridinilazole should become a first-line agent due to its antirecurrence
properties. Due to all of these reasons, the results
from the planned phase III study are eagerly anticipated.

Funding
This paper was not funded.

[waterloo01] 27/2/2019 07:12

Excellent volume again yesterday. ADR's are 5:1 to shares on AIM so 136k traded equals around 600k AIM shares.

[football] 26/2/2019 23:15

Summit Therapeutics
Clinical Research Associate

[kirk 6] 26/2/2019 21:50

Midatech went up over 300% so hopefully our turn tomorrow on the Nasdaq! This will motor soon.

[robizm] 26/2/2019 21:46

Do We normally follow nasdaq. Am new to this share

[chrisatrdg] 26/2/2019 21:45

NASDAQ close was $1.87 (plus 28.97%) = 28p roll on Wednesday.

[algernon2] 26/2/2019 21:07

34.1% up now on Nasdaq, Yeehaw! Go baby go!

[kirk 6] 26/2/2019 21:02

29p open hopefully tomorrow with a run into 30s

[waterloo01] 26/2/2019 19:15

Decent volume last few days on Nasdaq. Currently up 13%. Long way to go in every sense.

[kirk 6] 26/2/2019 14:48

US market open = uk market takedown KO. People buy all morning and price rise gets wiped out by tiny trade on the Nasdaq.Lago more to your comment could be the exact opposite were as people getting over excited, more people/ the market not giving any premium value to yesterday's news whatsoever and taking consideration large finding at 25p. Lag maybe this need pointing out

[lagosboy] 26/2/2019 14:47

football - the problem I have with Glynn is his presentational style. He over promises and and never delivers- a bad combination for getting seriously burnt as a shareholder. Antisoma is a perfect example- Glynn cleaned out shareholders there at the 12th hour and even DMD seemed to be going well if one believed the hype from Glynn, and we all know what happened there.

I suspect Summ is probably far too late for the party anyway - trials and FDA approval which will be rigorous are years away and more importantly millions of dollars away.

Summ is just simply too small, it needs to sell on or partner very early on, but approach leaves Glyn out in the cold and unable to fly around the globe, wasting shareholder money, attending conferences.

[robizm] 26/2/2019 12:42

If you want to know the horrors of antibiotics look at motif bio. Passed two stage 3 tests and still did not get approved. I hope the stuff in phase 3 works well because summ will need more money come end of January 2020.

[waterloo01] 26/2/2019 09:53

True still need safety and dosing trials but as it's so specific in it's target it's not likely to have side effects.

[football] 26/2/2019 09:43

lagosboy Didn't Glynn say in an earlier video or podcast that antibiotics isn't like other research it either works or it doesn't and you just have to refine it just like an ever decreasing circle to you get the right formula, so if we are on the right track hopefully this time it's just sorting out the wheat from the chaff.

As for roundup less than five months a few years back to kill every bit of Japanese knotweed in the garden and neighbours but stinging nettles keep on coming back the gits

[lagosboy] 26/2/2019 09:33

I would caution not to get ahead of yourselves - this is a preclinical study so the issue of toxicity has yet to be considered.

Roundup is potent in killing weeds but it kills everything else that it comes into contact with !

Usual SUMM/Glynn Edwards style - builds up investor hopes only to disappoint. I thought the wording of the RNS was overblown and unnecessary.

[kirk 6] 25/2/2019 21:53

Strong day in US hoping this seller is nearly gone!

[kirk 6] 25/2/2019 20:02

Sounds very promising reckon these are due a massive re rate

[chrisatrdg] 25/2/2019 19:36

Summit Therapeutics shoots higher as data shows SMT-57 antibiotic potent against diverse, global gonorrhoeae strains:

investors.co.uk/companies/news/215227/summit-therapeutics-shoots-higher-as-data-shows-smt-57-antibiotic-potent-against-diverse-global-gonorrhoeae-strains-215227.html

Edit: The link may not work but you will know where to look

[algernon2] 25/2/2019 14:31

Bravo Glyn and Summit.